Plus, JCPenney is expected to file for bankruptcy today, the Trump administration moved to block chip shipments to Huawei, and the FDA issued a warning about Abbott Labs’ rapid COVID-19 test.
Read MorePlus, the FDA granted emergency use authorization for Abbott Laboratories’ COVID-19 antibodies test, oil is higher after Saudi Arabia said it would cut production by an additional 1 million barrels per day, and Constellation Brands got a downgrade from MKM Partners.
Read MorePlus, Sorrento Therapeutics is partnering with New York’s Mount Sinai on developing a antibody cocktail to shield health care workers and other front-line workers from the coronavirus, Tesla is resuming production at its Fremont, CA plant, and Disney shares got a boost from tickets selling out within minutes for the reopening of its Shanghai Disneyland park.
Read MorePlus, stocks are higher on hopes for trade talks between the U.S. and China, weekly jobless claims came in at 3.17 million, luxury department store Neiman Marcus filed for Chapter 11, and Tesla has temporarily halted production at its Shanghai plant.
Read MorePlus, Tyson Foods said net income fell 15% last quarter due to the coronavirus, J.Crew became the first major retailer to file for bankruptcy amid the pandemic, and PG&E shares are up after an upgrade from UBS.
Read MorePlus, the FDA is moving at “lightning speed” to review data on Gilead’s remdesivir treatment for COVID-19, Tesla CEO Musk decried stay-at-home orders in an expletive-filled earnings call rant, Macy’s plans to reopen all of its stores within the next six weeks, and American Airlines reported it lost more than $2.2 billion last quarter.
Read MoreBuy Price – $13.75 or better Sell Price – TradersPro Sell Signal Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company […]
Read MoreHealthcare stocks remain a prime area of focus for my analysis right now, and will continue to be as all of North America struggles to find a justifiable reason to get national economies restarted. I think that the basis for any kind of reopening of businesses has to come from evidence not merely that infections […]
Read MorePlus, oil rebounded, the Senate passed the $484 billion supplemental coronavirus relief package, Delta reported its first quarterly loss in five years, and Chipotle said its digital sales more than doubled in Q1.
Read MoreBuy Price – $7.30 or better Sell Price – TradersPro Sell Signal NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; […]
Read MorePlus, lawmakers are nearing an agreement on additional funding for the small business aid program, Shake Shack said it will be returning the $10 million federal loan it’s set to receive to provide more needed funding to independent restaurants, and United Airlines said it recorded a $2.1 billion loss in Q1.
Read MorePlus, the program to provide emergency loans to small businesses amid the coronavirus crisis has run out of money, the Trump administration is expected to unveil its plan to reopen state economies, earnings season marched on with Morgan Stanley and Abbott Laboratories, and Mastercard got a downgrade.
Read MorePlus, negative bank earnings kept rolling in, coronavirus cases surpassed 2 million globally, Abbott Laboratories released a new COVID-19 antibodies test, and Apple released a new, budget-friendly iPhone.
Read MorePlus, earnings season began with JPMorgan, Wells Fargo, and Johnson & Johnson reporting, Roku shares are higher after the streaming device maker said it netted 3 million active accounts in the first quarter, and Tesla shares are up after an upgrade.
Read MoreTrade Setup Buy Target $2.26 Sell Target $2.97 Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated […]
Read More